The U.S. Food and Drug Administration has approved Genentech's Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular ...

The U.S. Food and Drug Administration (FDA) has approved ranibizumab injection (Susvimo, 100 mg/mL; Genentech) for the ...

Seven months after the FDA signed off on a reintroduction of Roche’s eye implant Susvimo, the U.S. regulator has broadened ...

Feb. 6, 2025 — The FDA has approved a new implantable treatment for adults with diabetic macular edema (DME) after studies showed that it could help maintain vision with as few as two ...

Roche’s Susvimo, a refillable eye implant for diabetic macular edema, provides continuous delivery of ranibizumab, showing ...

Susvimo is the first and only continuous delivery treatment that offers an alternative to regular eye injections to treat ...

(RTTNews) - EyePoint Pharmaceuticals, Inc. (EYPT), Wednesday announced positive six-month results from the ongoing Phase 2 VERONA clinical trial, evaluating Duravyu for the treatment of diabetic ...

Scientists remain puzzled as to why some individuals taking popular weight loss and diabetes medications such as Ozempic and ...

EyePoint Pharmaceuticals Inc. (EYPT), which reported positive interim 16-week data from its phase II VERONA clinical trial last ...

Hong Kong biotech start-up works with university partners to conduct global clinical trials studying prevalent eye diseases.

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Susvimo (ranibizumab) 100 mg/mL for treating diabetic macular edema. Susvimo is the first and only ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug ...